PubMed=19544433; DOI=10.1002/stem.98
Kelly J.J.P., Stechishin O.D.M., Chojnacki A., Lun X.-Q., Sun B.-C., Senger D.L., Forsyth P., Auer R.N., Dunn J.F., Cairncross J.G., Parney I.F., Weiss S.
Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Stem Cells 27:1722-1733(2009)

PubMed=20388696; DOI=10.1093/neuonc/noq031
Kelly J.J.P., Blough M.D., Stechishin O.D.M., Chan J.A.W., Beauchamp D.C., Perizzolo M., Demetrick D.J., Steele L., Auer R.N., Hader W.J., Westgate M.R., Parney I.F., Jenkins R.B., Cairncross J.G., Weiss S.
Oligodendroglioma cell lines containing t(1;19)(q10;p10).
Neuro-oncol. 12:745-755(2010)

PubMed=20593219; DOI=10.1007/s11060-010-0283-9
Blough M.D., Beauchamp D.C., Westgate M.R., Kelly J.J.P., Cairncross J.G.
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.
J. Neurooncol. 102:1-7(2011)

PubMed=26095605; DOI=10.1016/j.stemcr.2015.05.010
Cusulin C., Chesnelong C., Bose P., Bilenky M., Kopciuk K., Chan J.A.W., Cairncross J.G., Jones S.J.M., Marra M.A., Luchman H.A., Weiss S.
Precursor states of brain tumor initiating cell lines are predictive of survival in xenografts and associated with glioblastoma subtypes.
Stem Cell Reports 5:1-9(2015)

PubMed=27006494; DOI=10.1158/1078-0432.CCR-15-1798
Lun X.-Q., Wells J.C., Grinshtein N., King J.C., Hao X.-G., Dang N.-H., Wang X.-L., Aman A., Uehling D., Datti A., Wrana J.L., Easaw J.C., Luchman H.A., Weiss S., Cairncross J.G., Kaplan D.R., Robbins S.M., Senger D.L.
Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma.
Clin. Cancer Res. 22:3860-3875(2016)